Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 16/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 16/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 13/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 13/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL27664432 | 0.89 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| Nitric Acid SCHEMBL2850392 | 0.89 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL2396561 | 0.81 | KCNQ3 (0.51) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL16785423 | 0.81 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL27690793 | 0.81 | KCNQ3 (0.51) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL9955261 | 0.77 | NPSR1 (0.46) | KCNQ3KCNQ2ALDH1A1ADRA2AADRA2B | |
| SCHEMBL30568974 | 0.76 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL6361424 | 0.76 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL8974170 | 0.76 | PTPN1 (0.51) | ADRA2AADRA2B | |
| Guanidine SCHEMBL28160437 | 0.75 | HIF1A (0.35) | KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012085166-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-06-28 | — | — | WO | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-1399440-B1 | 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050228005-A1 | Protein kinase inhibitors and uses thereof | MOON YOUNG C | 2005-10-13 | — | — | US | disclosed |
| US-6825190-B2 | 4-(1,2- OR 2,1-BENZOXAZOL-5-YL)-2-AMINOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-30 | — | — | US | disclosed |
| WO-2002102800-A9 | 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1399440-A1 | 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040009996-A1 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-01-15 | — | — | US | disclosed |
| WO-2002102800-A1 | 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | KCNQ3 3201/4885KCNQ2 3057/4885KCNE1 3319/4885 |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | KCNQ3 3201/4885KCNQ2 3057/4885KCNE1 3319/4885 |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | KCNQ3 3201/4885KCNQ2 3057/4885KCNE1 3319/4885 |
| US-20040009996-A1 | Protein kinase inhibitors and uses thereof | GSK3A, GSK3B, JAK3 | KCNQ3 3816/4885KCNQ2 4188/4885KCNE1 3156/4885 |
| US-20050228005-A1 | Protein kinase inhibitors and uses thereof | GSK3A, JAK3, GSK3B | KCNQ3 3227/4885KCNQ2 3807/4885KCNE1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.